Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.

Generali Asset Management SPA SGR has purchased 11,358 shares of Regeneron Pharmaceuticals, valued at approximately $8.1 ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Lifeworks Advisors LLC increased its stake in Regeneron Pharmaceuticals by 31.5%, now holding 6,743 shares worth $4.8 million. Other major institutional investors also adjusted their positions, with ...

Leerink Partners reiterated their market perform ... after buying an additional 1,912,771 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of 2seventy ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

On Tuesday, 11 March 2025, MacroGenics (NASDAQ: MGNX) presented at Leerink’s Global Healthcare Conference 2025. The company showcased its robust pipeline of cancer therapeutics and strategic ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

The Cambridge, Massachusetts-based biotech had divested its cell therapy R&D programs to Regeneron for $5 million upfront in early 2024. As the Leerink team noted, the company’s remaining ...

In a note sent to investors Tuesday, Leerink Partners analyst Daina Graybosch ... as 2seventy already divested its R&D assets to Regeneron and Novo Nordisk, and [Bristol Myers Squibb] manufactures ...